Page last updated: 2024-12-07
versiconal
Description
versiconal: RN not in Chemline 7/83; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
versiconal : A secondary metabolite that is an intermediate in the biosynthesis of afflatoxin. Can exist as both a tricyclic anthraquinone-hydroxyaldehyde form or as a tetracyclic anthrafuran form. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
versiconal hemiacetal : An anthrafuran that is 2,3-dihydroanthra[2,3-b]furan-5,10-dione substituted at positions 2, 4, 6 and 8 by hydroxy groups and at position 3 by a 2-hydroxyethyl group. An intermediate in the biosynthesis of aflatoxin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (9)
| Synonym |
|---|
| versiconal |
| (2s,3s)-2,4,6,8-tetrahydroxy-3-(2-hydroxyethyl)anthra[2,3-b]furan-5,10-dione |
| versiconal hemiacetal form |
| versiconal hemiacetal |
| CHEBI:71638 |
| 2,4,6,8-tetrahydroxy-3-(2-hydroxyethyl)-2,3-dihydroanthra[2,3-b]furan-5,10-dione |
| versiconal anthrafuran form |
| Q27139776 |
| 2,4,6,8-tetrahydroxy-3-(2-hydroxyethyl)-2,3-dihydronaphtho[2,3-f][1]benzofuran-5,10-dione |
Drug Classes (3)
| Class | Description |
|---|
| anthrafuran | Any organic heterotetracyclic compound consisting of a furan ring ortho-fused to an anthracene. |
| lactol | Cyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues. |
| versiconal | A secondary metabolite that is an intermediate in the biosynthesis of afflatoxin. Can exist as both a tricyclic anthraquinone-hydroxyaldehyde form or as a tetracyclic anthrafuran form. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |